Crossmark

β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo

Published Online: 2024-06-23

Authors

Deng, Meng

Yan, Peijie

Gong, Hui

Li, Guiqiu

Wang, Jianjie http://orcid.org/0009-0005-3142-4812
Funding

Funding for this research was provided by:

the Natural Science Foundation of Guangdong Province, China (2020A1515011303)

Huazhong University of Science and Technology Union Shenzhen Hospital Funds (YN2022013)

Nanshan District Health System Major Science and Technology Project (NSZD2023015)
License Information

Text and Data Mining valid from 2024-06-23

Version of Record valid from 2024-06-23
More Information

Article History

Received: 3 December 2023

Accepted: 12 June 2024

First Online: 23 June 2024

Declarations

:

: All extractions were reviewed and approved by the medical ethics committee of Jiamusi University with informed patient consent. Animal experiments were approved and supervised by the Animal Ethics Committee of Jiamusi University.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current